Get the Stockscreener App
6.89
4.08%
0.27
Immuneering Corp stock is traded at $6.89, with a volume of 2.02M.
It is up +4.08% in the last 24 hours and up +12.77% over the past month.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
See More
Previous Close:
$6.62
Open:
$6.5
24h Volume:
2.02M
Relative Volume:
1.15
Market Cap:
$286.42M
Revenue:
$317.00K
Net Income/Loss:
$-53.47M
P/E Ratio:
-3.6455
EPS:
-1.89
Net Cash Flow:
$-49.31M
1W Performance:
+0.29%
1M Performance:
+12.77%
6M Performance:
+526.36%
1Y Performance:
+256.99%
1-Day Range:
$5.98
$6.95
1-Week Range:
$5.98
$7.15
52-Week Range:
$1.10
$10.08
Immuneering Corp Stock (IMRX) Company Profile
Name
Immuneering Corp
Sector
Industry
Phone
617-500-8080
Address
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Compare IMRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
6.89 | 418.64M | 317.00K | -53.47M | -49.31M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-25 | Initiated | Leerink Partners | Outperform |
| Dec-13-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Mar-15-24 | Downgrade | Jefferies | Buy → Hold |
| Mar-15-24 | Reiterated | Needham | Buy |
| Mar-15-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-01-23 | Initiated | Needham | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Apr-19-23 | Upgrade | Mizuho | Neutral → Buy |
| Apr-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-30-23 | Initiated | Mizuho | Neutral |
| Feb-03-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-08-22 | Initiated | Chardan Capital Markets | Buy |
| Apr-01-22 | Initiated | Oppenheimer | Outperform |
| Jan-07-22 | Initiated | Piper Sandler | Overweight |
View All
Immuneering Corp Stock (IMRX) Latest News
What data driven models say about Immuneering Corporation’s futureMarket Performance Recap & Consistent Profit Alerts - newser.com
Is Immuneering Corporation stock poised for growthJuly 2025 Macro Moves & Capital Efficiency Focused Ideas - newser.com
Will Immuneering Corporation stock attract more institutional investors2025 Year in Review & High Accuracy Swing Entry Alerts - fcp.pa.gov.br
Can Immuneering Corporation stock reach $100 price target2025 Technical Patterns & Smart Investment Allocation Insights - newser.com
Top chart patterns to watch in Immuneering CorporationForecast Cut & Smart Money Movement Alerts - newser.com
Can Immuneering Corporation stock sustain institutional interest2025 Sector Review & Proven Capital Preservation Methods - newser.com
Immuneering Corporation (IMRX) stock forecast and price target - Yahoo! Finance UK
Immuneering (IMRX) Expected to Announce Earnings on Wednesday - MarketBeat
Why Immuneering Corporation stock is recommended by analystsWeekly Trend Summary & AI Powered Market Trend Analysis - newser.com
How Immuneering Corporation stock compares to growth peersMarket Growth Review & Fast Exit and Entry Trade Guides - newser.com
How Immuneering Corporation stock valuations compare to rivalsJuly 2025 Drop Watch & Fast Moving Trade Plans - newser.com
Will Immuneering Corporation stock outperform value stocks2025 Historical Comparison & AI Forecasted Entry/Exit Points - newser.com
Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025 - The Manila Times
Trend analysis for Immuneering Corporation this weekAnalyst Downgrade & High Conviction Buy Zone Alerts - newser.com
Has Immuneering Corporation formed a bullish divergencePortfolio Return Report & Growth-Oriented Investment Plans - newser.com
Best data tools to analyze Immuneering Corporation stockAnalyst Upgrade & Free High Accuracy Swing Entry Alerts - newser.com
Is Immuneering Corporation stock ready for a breakoutJuly 2025 Recap & Pattern Based Trade Signal System - newser.com
Is Immuneering Corporation stock undervalued vs historical averagesTrade Signal Summary & Free Fast Gain Swing Trade Alerts - newser.com
Is Immuneering Corporation stock attractive for growth ETFsDividend Hike & High Accuracy Trade Alerts - fcp.pa.gov.br
Is Immuneering Corporation stock positioned well for digital economyGap Up & Entry Point Strategy Guides - newser.com
What indicators show strength in Immuneering CorporationWeekly Loss Report & Accurate Intraday Trading Signals - newser.com
Can Immuneering Corporation rally from current levelsQuarterly Investment Review & Real-Time Market Sentiment Alerts - newser.com
Can momentum traders help lift Immuneering CorporationPortfolio Value Summary & Stepwise Swing Trade Plans - newser.com
Immuneering (NASDAQ:IMRX) Upgraded at Leerink Partnrs - MarketBeat
Immuneering (NASDAQ:IMRX) Stock Rating Upgraded by Leerink Partnrs - Defense World
Leerink Partners Initiates Coverage on Immuneering (NASDAQ:IMRX) - MarketBeat
What’s the recovery path for long term holders of Immuneering CorporationWeekly Stock Summary & Risk Adjusted Buy and Sell Alerts - newser.com
This Immuneering Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Published on: 2025-10-31 05:51:06 - newser.com
How to build a dashboard for Immuneering Corporation stock2025 Earnings Surprises & Technical Buy Zone Confirmations - newser.com
Will Immuneering Corporation stock benefit from automationJuly 2025 Volume & Daily Entry Point Alerts - newser.com
Can machine learning forecast Immuneering Corporation recoveryJuly 2025 Weekly Recap & High Accuracy Investment Signals - newser.com
How strong is Immuneering Corporation stock balance sheetJuly 2025 Setups & Expert Verified Stock Movement Alerts - newser.com
What institutional flow reveals about Immuneering CorporationForecast Cut & Capital Efficient Trade Techniques - newser.com
Forecasting Immuneering Corporation price range with options dataMarket Activity Summary & Daily Profit Maximizing Trade Tips - newser.com
Immuneering Corp Stock (IMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.44%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):